)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Dexcom
Dexcom (DXCM) investor relations material
Dexcom Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 revenue was $1,344.5M, up 11% YoY on reported and organic bases; U.S. growth was 14% and international growth was 5%.
Gross profit increased 18% and operating income increased 35% on a GAAP basis; GAAP net income declined 3%, while non-GAAP diluted EPS reached a quarterly record $0.73.
Nine-month revenue reached $3,844.8M, up 13% YoY; operating income rose 53% and net income rose 27%.
Growth reflected higher sensor volume and customer expansion, alongside U.S. share gains and near-record global new patient starts.
Financial highlights
Revenue was $1,344.5M vs. $1,209.3M in Q3 2025; U.S. revenue was $969.8M, up 14%, and international revenue was $374.7M, up 5%.
GAAP gross profit was $864.4M vs. $731.4M, with gross margin of 64.3% vs. 60.5%; non-GAAP gross profit was $875.3M and margin was 65.1% vs. 61.3%.
GAAP operating income was $327.2M vs. $242.5M; non-GAAP operating income was $339.5M vs. $272.9M.
GAAP net income was $275.1M vs. $283.8M and diluted EPS was $0.72 vs. $0.70; non-GAAP net income was $275.0M vs. $242.5M and EPS was $0.73 vs. $0.61.
Nine-month gross profit was $2,444.7M, operating income $900.8M, and net income $723.7M; diluted EPS was $1.87 vs. $1.42.
Outlook and guidance
FY2026 revenue guidance increased to $5.20B–$5.25B, representing 12%–13% growth; the midpoint reflects Q3 outperformance partly offset by ~$5M of incremental FX headwinds and implies 10% Q4 growth.
FY2026 non-GAAP gross margin guidance remains ~64%; operating margin guidance increased to ~24% and Adjusted EBITDA margin guidance to ~32%.
Ireland startup costs are expected to weigh on Q4 and early 2027; G7 15 Day adoption, manufacturing efficiencies and the absence of Ireland expansion costs are expected to support later margin progression.
Medicare coverage for type 2 non-insulin users is expected to be decided this year, with coverage currently anticipated to take effect mid-2027; G8 remains targeted for late 2027 or early 2028, subject to regulatory review.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Dexcom
- Q4 revenue grew 26% organically as FDA submissions and G7 integrations advanced.DXCM
Q4 2023 - CONNECT data, expanded coverage, and product innovation set stage for accelerated growth.DXCMWells Fargo 21st Annual Healthcare Conference
- Q2 2026 revenue rose 13%, net income 39%, margins and guidance up, $600M shares repurchased.DXCMQ2 2026
- Double-digit growth, new launches, and expanded access drive a strong outlook through 2030.DXCMInvestor Day 2026
- Strong innovation and global expansion drive double-digit growth and market leadership.DXCMInvestor presentation
- Q1 2026 delivered 15% revenue growth, margin expansion, record new patient starts, and strong cash flow.DXCMQ1 2026
- Raised guidance, strong patient growth, and expanding coverage drive positive outlook.DXCMBaird Global Healthcare Conference 2025
- Q3 2024 saw 2–3% revenue growth, strong international gains, and a $750M share repurchase.DXCMQ3 2024
- Q1 2025 revenue up 14% organically; $750M buyback, FDA G7 clearance, and PBM expansion highlight results.DXCMQ1 2025
Next Dexcom earnings date
Q4 202611 Feb, 2027
Dexcom
Next Dexcom earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Dexcom, Inc., focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company's products include Dexcom G4 PLATINUM System, Dexcom G5 Mobile CGM System, and its interoperable systems, as well as other clinical diagnostic products. It offers its products to hospitals; physicians' offices specializing in diabetes treatment; ambulatory surgical centers; clinical practice settings; corporate wellness programs; and individual patients. The company markets its products directly to physicians and their specialties, including endocrinologists; general practitioners; obstetricians/gynecologists; pediatricians; family physicians; doctors practicing in health care clinics or managed facilities; diabetologists; and internists. The company was incorporated in 1999.